These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22894572)

  • 41. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
    Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
    Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
    Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
    Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-cancer mortality at 11 years of follow-up.
    Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Páez A; Määttänen L; Bangma CH; Aus G; Carlsson S; Villers A; Rebillard X; van der Kwast T; Kujala PM; Blijenberg BG; Stenman UH; Huber A; Taari K; Hakama M; Moss SM; de Koning HJ; Auvinen A;
    N Engl J Med; 2012 Mar; 366(11):981-90. PubMed ID: 22417251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
    Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
    Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
    de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
    Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.
    Heijnsdijk EAM; Adolfsson J; Auvinen A; Roobol MJ; Hugosson J; de Koning HJ
    Eur Urol; 2019 Sep; 76(3):276-279. PubMed ID: 31031050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expected population impacts of discontinued prostate-specific antigen screening.
    Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
    Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.